Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results
Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinua...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 1993, Vol.11 (s1), p.281-291 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 291 |
|---|---|
| container_issue | s1 |
| container_start_page | 281 |
| container_title | Leukemia & lymphoma |
| container_volume | 11 |
| creator | Alimena, Giuliana Meloni, Giovanna De Cuia, M. Rosaria Rondinelli, M. Beatrice Coco, Francesco Lo Montefusco, Enrico Mancini, Marco Pinto, Rita Nanni, Mauro Cedrone, Michele Fabritiis, Paolo De Mandelli, Franco |
| description | Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40%, 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19%, 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches. |
| doi_str_mv | 10.3109/10428199309047900 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76094840</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76094840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-462f511fa037976128d5b01697b25ef453c03622ba8c849d53aae55b472e51c3</originalsourceid><addsrcrecordid>eNp9kV-L1DAUxYMo6zr6AXwQ8uRb3SRN_0R9GcrqLsyi6LyX2_Z2mjVNxiRlma_ipzXDDAsi-pQL55wfuecS8pqzdzln6oozKWquVM4Uk5Vi7Am55EyoTEiWPz3OUmTJIJ-TFyHcM8YKVYoLcpG8opLlJfl1BxZ2OKON1I20mbyzuqd3BzROD3SDyw-cNVBtH7WvEwSkDzpOdL1EZ9zOLYF-jzjTBo2hWw827A3YCFE7S8EOdG32E2SC3tqIfsQEek-bQ3Q7tBgT8-hpjE54MPQbhsXE8JI8G8EEfHV-V2T76Xrb3GSbL59vm_Um62XOYiZLMRacj8DySlUlF_VQdIyXqupEgaMs8p7lpRAd1H0t1VDkAFgUnawEFrzPV-TtCbv37ueCIbazDn1aBCymxdqqZErWqc8V4Sdj710IHsd27_UM_tBy1h7P0f51jpR5c4Yv3YzDY-Lcf9I_nnRtR-dneHDeDG2Eg3F-TD32OhzR_8Z_-CM-IZg49eCxvXeLt6m2_3zuN3d9q5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76094840</pqid></control><display><type>article</type><title>Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Access via Taylor & Francis</source><creator>Alimena, Giuliana ; Meloni, Giovanna ; De Cuia, M. Rosaria ; Rondinelli, M. Beatrice ; Coco, Francesco Lo ; Montefusco, Enrico ; Mancini, Marco ; Pinto, Rita ; Nanni, Mauro ; Cedrone, Michele ; Fabritiis, Paolo De ; Mandelli, Franco</creator><creatorcontrib>Alimena, Giuliana ; Meloni, Giovanna ; De Cuia, M. Rosaria ; Rondinelli, M. Beatrice ; Coco, Francesco Lo ; Montefusco, Enrico ; Mancini, Marco ; Pinto, Rita ; Nanni, Mauro ; Cedrone, Michele ; Fabritiis, Paolo De ; Mandelli, Franco</creatorcontrib><description>Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40%, 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19%, 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428199309047900</identifier><identifier>PMID: 7902746</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Adult ; Blood Component Transfusion ; Blood Transfusion, Autologous ; Bone Marrow - pathology ; Bone Marrow Purging ; Bone Marrow Transplantation ; Combined Modality Therapy ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Hydroxyurea - therapeutic use ; Immunologic Factors - therapeutic use ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Italy - epidemiology ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Leukemia, Myeloid, Chronic-Phase - genetics ; Leukemia, Myeloid, Chronic-Phase - mortality ; Leukemia, Myeloid, Chronic-Phase - pathology ; Leukemia, Myeloid, Chronic-Phase - therapy ; Male ; Middle Aged ; Neoplastic Stem Cells - ultrastructure ; Prospective Studies ; Recombinant Proteins ; Remission Induction ; Survival Rate ; Treatment Outcome</subject><ispartof>Leukemia & lymphoma, 1993, Vol.11 (s1), p.281-291</ispartof><rights>1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1993</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-462f511fa037976128d5b01697b25ef453c03622ba8c849d53aae55b472e51c3</citedby><cites>FETCH-LOGICAL-c430t-462f511fa037976128d5b01697b25ef453c03622ba8c849d53aae55b472e51c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10428199309047900$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10428199309047900$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>315,781,785,4025,27928,27929,27930,59652,59758,60441,60547,61226,61261,61407,61442</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7902746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alimena, Giuliana</creatorcontrib><creatorcontrib>Meloni, Giovanna</creatorcontrib><creatorcontrib>De Cuia, M. Rosaria</creatorcontrib><creatorcontrib>Rondinelli, M. Beatrice</creatorcontrib><creatorcontrib>Coco, Francesco Lo</creatorcontrib><creatorcontrib>Montefusco, Enrico</creatorcontrib><creatorcontrib>Mancini, Marco</creatorcontrib><creatorcontrib>Pinto, Rita</creatorcontrib><creatorcontrib>Nanni, Mauro</creatorcontrib><creatorcontrib>Cedrone, Michele</creatorcontrib><creatorcontrib>Fabritiis, Paolo De</creatorcontrib><creatorcontrib>Mandelli, Franco</creatorcontrib><title>Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40%, 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19%, 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.</description><subject>Adult</subject><subject>Blood Component Transfusion</subject><subject>Blood Transfusion, Autologous</subject><subject>Bone Marrow - pathology</subject><subject>Bone Marrow Purging</subject><subject>Bone Marrow Transplantation</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Hydroxyurea - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Italy - epidemiology</subject><subject>Karyotyping</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Leukemia, Myeloid, Chronic-Phase - genetics</subject><subject>Leukemia, Myeloid, Chronic-Phase - mortality</subject><subject>Leukemia, Myeloid, Chronic-Phase - pathology</subject><subject>Leukemia, Myeloid, Chronic-Phase - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplastic Stem Cells - ultrastructure</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV-L1DAUxYMo6zr6AXwQ8uRb3SRN_0R9GcrqLsyi6LyX2_Z2mjVNxiRlma_ipzXDDAsi-pQL55wfuecS8pqzdzln6oozKWquVM4Uk5Vi7Am55EyoTEiWPz3OUmTJIJ-TFyHcM8YKVYoLcpG8opLlJfl1BxZ2OKON1I20mbyzuqd3BzROD3SDyw-cNVBtH7WvEwSkDzpOdL1EZ9zOLYF-jzjTBo2hWw827A3YCFE7S8EOdG32E2SC3tqIfsQEek-bQ3Q7tBgT8-hpjE54MPQbhsXE8JI8G8EEfHV-V2T76Xrb3GSbL59vm_Um62XOYiZLMRacj8DySlUlF_VQdIyXqupEgaMs8p7lpRAd1H0t1VDkAFgUnawEFrzPV-TtCbv37ueCIbazDn1aBCymxdqqZErWqc8V4Sdj710IHsd27_UM_tBy1h7P0f51jpR5c4Yv3YzDY-Lcf9I_nnRtR-dneHDeDG2Eg3F-TD32OhzR_8Z_-CM-IZg49eCxvXeLt6m2_3zuN3d9q5g</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>Alimena, Giuliana</creator><creator>Meloni, Giovanna</creator><creator>De Cuia, M. Rosaria</creator><creator>Rondinelli, M. Beatrice</creator><creator>Coco, Francesco Lo</creator><creator>Montefusco, Enrico</creator><creator>Mancini, Marco</creator><creator>Pinto, Rita</creator><creator>Nanni, Mauro</creator><creator>Cedrone, Michele</creator><creator>Fabritiis, Paolo De</creator><creator>Mandelli, Franco</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1993</creationdate><title>Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results</title><author>Alimena, Giuliana ; Meloni, Giovanna ; De Cuia, M. Rosaria ; Rondinelli, M. Beatrice ; Coco, Francesco Lo ; Montefusco, Enrico ; Mancini, Marco ; Pinto, Rita ; Nanni, Mauro ; Cedrone, Michele ; Fabritiis, Paolo De ; Mandelli, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-462f511fa037976128d5b01697b25ef453c03622ba8c849d53aae55b472e51c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Blood Component Transfusion</topic><topic>Blood Transfusion, Autologous</topic><topic>Bone Marrow - pathology</topic><topic>Bone Marrow Purging</topic><topic>Bone Marrow Transplantation</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Hydroxyurea - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Italy - epidemiology</topic><topic>Karyotyping</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Leukemia, Myeloid, Chronic-Phase - genetics</topic><topic>Leukemia, Myeloid, Chronic-Phase - mortality</topic><topic>Leukemia, Myeloid, Chronic-Phase - pathology</topic><topic>Leukemia, Myeloid, Chronic-Phase - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplastic Stem Cells - ultrastructure</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alimena, Giuliana</creatorcontrib><creatorcontrib>Meloni, Giovanna</creatorcontrib><creatorcontrib>De Cuia, M. Rosaria</creatorcontrib><creatorcontrib>Rondinelli, M. Beatrice</creatorcontrib><creatorcontrib>Coco, Francesco Lo</creatorcontrib><creatorcontrib>Montefusco, Enrico</creatorcontrib><creatorcontrib>Mancini, Marco</creatorcontrib><creatorcontrib>Pinto, Rita</creatorcontrib><creatorcontrib>Nanni, Mauro</creatorcontrib><creatorcontrib>Cedrone, Michele</creatorcontrib><creatorcontrib>Fabritiis, Paolo De</creatorcontrib><creatorcontrib>Mandelli, Franco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alimena, Giuliana</au><au>Meloni, Giovanna</au><au>De Cuia, M. Rosaria</au><au>Rondinelli, M. Beatrice</au><au>Coco, Francesco Lo</au><au>Montefusco, Enrico</au><au>Mancini, Marco</au><au>Pinto, Rita</au><au>Nanni, Mauro</au><au>Cedrone, Michele</au><au>Fabritiis, Paolo De</au><au>Mandelli, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>1993</date><risdate>1993</risdate><volume>11</volume><issue>s1</issue><spage>281</spage><epage>291</epage><pages>281-291</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40%, 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19%, 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>7902746</pmid><doi>10.3109/10428199309047900</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 1993, Vol.11 (s1), p.281-291 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76094840 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Access via Taylor & Francis |
| subjects | Adult Blood Component Transfusion Blood Transfusion, Autologous Bone Marrow - pathology Bone Marrow Purging Bone Marrow Transplantation Combined Modality Therapy Female Hematopoietic Stem Cell Transplantation Humans Hydroxyurea - therapeutic use Immunologic Factors - therapeutic use Interferon alpha-2 Interferon-alpha - therapeutic use Italy - epidemiology Karyotyping Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Leukemia, Myeloid, Chronic-Phase - genetics Leukemia, Myeloid, Chronic-Phase - mortality Leukemia, Myeloid, Chronic-Phase - pathology Leukemia, Myeloid, Chronic-Phase - therapy Male Middle Aged Neoplastic Stem Cells - ultrastructure Prospective Studies Recombinant Proteins Remission Induction Survival Rate Treatment Outcome |
| title | Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T04%3A39%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase%20with%20Autologous%20Stem%20Cell%20Transplantation%20and%20Alpha-2%20Interferon:%20Cytogenetic%20and%20Clinical%20Results&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Alimena,%20Giuliana&rft.date=1993&rft.volume=11&rft.issue=s1&rft.spage=281&rft.epage=291&rft.pages=281-291&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428199309047900&rft_dat=%3Cproquest_pubme%3E76094840%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76094840&rft_id=info:pmid/7902746&rfr_iscdi=true |